INOVIO PHARMACEUTICALS, INC.

INO

Held by 2 specialist biotech funds

2 funds opened new positions. Next phase2 readout (INO-5401): Dec 2026. Short interest: 22.3% of float.

BiotechnologyCEO: Jacqueline E. SheaIPO: 1998Website ↗

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

Catalysts

Phase 3NegativeQ2 2007Head Neck CancerNCT00198328

Primary: Function status at 4 months using the performance status scale for head and neck cancer (PSSHN) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck (EORTC-QLC-H&N35) (4 Months)Enrollment:84/84Sites: 1RANDOMIZED, TREATMENT

Phase 3NegativeQ2 2007Head and Neck CancerNCT00198315

Phase 2PositiveQ2 2014VGX 3100Cervical Intraepithelial NeoplasiaNCT01304524

Primary: Number of Participants with Histopathological Regression of Cervical Lesions to CIN 1 or Less as a Measure of Efficacy. (36 weeks)Enrollment:167/167Sites: 43RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2017INO-3112Head and Neck Squamous Cell CancerNCT02163057

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Event (SAEs) (Up to 6 months post last dose)Enrollment:22/22Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q3 2017INO-3112Cervical CancerNCT02172911

Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) (Up to 36 weeks)Enrollment:10/10Sites: 3NON_RANDOMIZED, TREATMENT

Phase 2Q2 2020VGX-3100Anal NeoplasmNCT03499795

Primary: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36 (Week 36)Enrollment:23/23Sites: 3NA, TREATMENT

Phase 3PositiveQ3 2020VGX-3100Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSILNCT03185013

Primary: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples (Week 36)Enrollment:201/201Sites: 60RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2020VGX-3100Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN)NCT03180684

Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples (Week 48)Enrollment:33/33Sites: 15RANDOMIZED, TREATMENT

Phase 3Q3 2022VGX-3100Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSILNCT03721978

Primary: Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples (At Week 36)Enrollment:203/203Sites: 53RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ3 2022INO-4800Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co V-2), COVID-19 DiseaseNCT04642638

Primary: Phase 2: Change From Baseline in Antigen-specific Cellular Immune Response Measured by Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Assay (Baseline up to Week 6)Enrollment:1,307/1,307Sites: 27RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2PositiveQ4 2022INO-3107Respiratory PapillomatosisNCT04398433

Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs (From first dose of study drug through 30 days following the last dose (approximately up to Week 13))Enrollment:32/32Sites: 11NA, TREATMENT

Phase 2PositiveQ1 2023INO-4700Middle East Respiratory Syndrome Coronavirus (MERS-Co V)NCT04588428

Primary: Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEs (From the first dose of the study drug up to the end of the study (up to 48.7 weeks))Enrollment:192/192Sites: 6RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q2 2025INO-5401Urothelial CarcinomaNCT03502785

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) Treatment (Up to approximately 71 months)Enrollment:35/35Sites: 11NON_RANDOMIZED, TREATMENT

Phase 2Q4 2026INO-5401GlioblastomaNCT03491683

Primary: Percentage of Participants with Adverse Events (AEs) (From Day 0 to 30 days after the last dose of study treatment (non-serious AEs) and to 6 months after the last dose of study treatment (immune-related AEs, AEs of special interest and serious AEs) up to approximately 24 months)Enrollment:52/52Sites: 21NON_RANDOMIZED, TREATMENT

INOVIO PHARMACEUTICALS, INC.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research